Figure 1. Ab responses after 1 or 2 doses of mRNA vaccine.

(A) Schematic diagram of the sampling schedule. (B) IgG response to vaccination across all participants at each time point (defined in A). Anti-spike (y-axis) and anti-RBD (x-axis) IgG levels at indicated time points. The dark blue line is the median ratio in convalescent patients (340 samples collected 21–115 days after symptom onset). The red line is the seropositivity threshold, set to pass both a 1% FPR and greater than or equal to 3 SDs from the log₁₀ means of the negative controls. See Supplemental Table 5 for percentage of samples that pass these thresholds. (C) IgG responses to vaccination in patients with IMID. Violin plots show the relative ratios of RBD and spike at the indicated time points in patients with IMID under monotherapy and combination therapy (0.0039 μL sample used, see Supplemental Figure 1 for the second dilution and Supplemental Table 4 for conversion to BAU/mL). T1, n = 111; T2, n = 130; T3, n = 130; and T4, n = 87. The dot colors indicate the type of vaccine; Pfizer refers to BNT162b; Moderna to mRNA-1273; and mRNA mix = first dose BNT162b and second dose mRNA-1273. Black and gray lines indicate median and mean ratio values for each violin, respectively. Plots are faceted based on the groups/treatments. Comparisons were made by Dunn’s multiple comparisons test based only on the BNT162b/BNT162b group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. M/A+TNF inh, MTX/AZA+TNF inh.